FDA Clears Tymlos for Osteoporosis in Men
Tymlos is already available to treat postmenopausal women with osteoporosis.
The FDA has approved Radius Health’s Tymlos (abaloparatide), a parathyroid hormone related peptide analog, to increase bone density in men with osteoporosis at high risk of fracture. It was approved in April 2017 for postmenopausal women with osteoporosis.
Bruce Mitlak, M.D.
“Thirty percent of all hip fractures occur in men and approximately 25% of men over the age of 50 years will sustain an osteoporotic-related fracture,” Bruce Mitlak, M.D., chief medical officer of Radius, said in a press release. “Additionally, while the overall prevalence of fragility fractures is higher in women, men generally have higher rates of fracture-related mortality
This approval is based on the phase 3 ATOM study, a 12-month multicenter study designed to evaluate the efficacy and safety of abaloparatide 80 micrograms in men with osteoporosis.
The primary efficacy endpoint of the ATOM study was the percent change from baseline in bone mineral density (BMD) at the lumbar spine at 12 months, which was 8.5% in the Tymlos compared with 1.2% in the placebo group. In the study, 228 men were enrolled.
The most common treatment emergent adverse events were injection site reaction, dizziness, nasopharyngitis, arthralgia, bronchitis, hypertension, and headache. The results were published Oct. 3, 2022, in the Journal of Bone and Mineral Research.
Radius Health announced in June 2022 that it the company is being acquired by Gurnet Point Capital and Patient Square Capital in a transaction valued at about $890 million, including the assumption of debt. Radius will become a private company when completed.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
